Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 14/20 | 0.85 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.85 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ATP4A | P20648 | 3/20 | 0.32 |
| ▸ | ATP4B | P51164 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524354 | 1.00 | ERBB2 (0.85) | ERBB2MINK1GRM2ATP4AATP4B | |
| Hydrochloric Acid SCHEMBL5521546 | 0.99 | ERBB2 (0.83) | ERBB2MINK1GRM2ATP4AATP4B | |
| Hydrochloric Acid SCHEMBL5521540 | 0.99 | ERBB2 (0.83) | ERBB2MINK1GRM2ATP4AATP4B | |
| SCHEMBL5523702 | 0.94 | ERBB2 (0.75) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5523704 | 0.94 | ERBB2 (0.75) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| Mubritinib SCHEMBL94943 | 0.92 | ERBB2 (1.00) | ERBB2MINK1 | |
| Mubritinib SCHEMBL571874 | 0.92 | ERBB2 (1.00) | ERBB2MINK1 | |
| SCHEMBL4665952 | 0.91 | ERBB2 (0.71) | ERBB2MINK1 | |
| SCHEMBL4665949 | 0.91 | ERBB2 (0.71) | ERBB2MINK1 | |
| Mubritinib SCHEMBL6758913 | 0.91 | ERBB2 (0.98) | ERBB2MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100386325-C | Oxazole derivatives, their manufacture and use as pharmaceutical formulations | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | CN | claimed |
| US-7205325-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | claimed |
| JP-2006515019-A | — | — | 2006-05-18 | — | — | JP | claimed |
| CN-1764660-A | Novel oxazole derivatives, their manufacture and use as pharmaceutical formulations | HOFFMANN LA ROCHE (CH) | 2006-04-26 | — | — | CN | claimed |
| EP-1613623-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-11 | — | — | EP | claimed |
| US-20040209933-A1 | Oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | US | claimed |
| WO-2004085434-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | claimed |
| CN-100386325-C | Oxazole derivatives, their manufacture and use as pharmaceutical formulations | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | CN | disclosed |
| US-7205325-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| CN-1764660-A | Novel oxazole derivatives, their manufacture and use as pharmaceutical formulations | HOFFMANN LA ROCHE (CH) | 2006-04-26 | — | — | CN | disclosed |
| EP-1613623-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-20040209933-A1 | Oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | US | disclosed |
| WO-2004085434-A1 | NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209933-A1 | Oxazole derivatives | OXA1L, SULT1E1, CYP3A7 | ERBB2 1048/4885MINK1 1545/4885GRM2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.